On August 22, 2022, EvopointBiosciences Co., Ltd. (here in after referred to as Evopoint) and Porton PharmaSolutions (stock ticker: 300363, stock abbreviation: Porton) jointly announceda strategic partnership. The two parties will carry out long-term strategiccooperation around the integrated customized R&D, production and supply ofinnovative drugs. It marks the deepening of the 5-year cooperation betweenEvopoint and Porton in the past to a new stage of development, and is also animportant milestone in the friendly win-win cooperation between the two parties.Mr. Le Meijie, General Manager of Evopoint, Mr. Ju Nianfeng, one of thecofounder, Chairman and General Manager of Porton, and Mr. Ji Yaohui, SeniorDeputy General Manager and General Manager of Small Molecular BusinessDepartment of Porton, led key team members from both parties to attend thesigning ceremony.
Evopoint and Porton haveofficially started business cooperation since 2017, with many cooperationprojects under implementation at present. Since its establishment for 5 years,Evopoint has devoted itself to constructing optimal targeted treatmentplatform, antibiotic platform and PROTAC platform. At present, 6 products inEvopoint are under clinical development at home and abroad, and 15 products areundergoing preclinical trials. In April 2022, FDA approved XNW4107 developed byEvopoint to be involved in the international key Phase III clinical trialscheme for indications of HAP/VAP. Its core products include BLI inhibitors,EZH2 inhibitors, hURAT1 inhibitors, PORCN (Wnt) inhibitors, etc. in the fieldsof tumors, anti-infection and metabolic diseases primarily. In the aspect ofoperation model, Evopoint adopts a global clinical development strategycombining efficient internal R&D and outsourcing services to accelerateproduct launch.
Porton always regards ourChinese market as its important strategic marketing, actively expands themarket of high-quality customers in China, and supports drug development ofdomestic customers with the same standards of serving overseas pharmaceuticalcustomers for >17 years. At present, Porton has established an"end-to-end" service platform to support the market demand ofdomestic key customers. With the establishment of Minhang (Shanghai) R&DCenter of Porton in the fourth quarter of 2022 and the continuous constructionof new services and capabilities, we look forward to enabling increasingly moreChinese customers to develop innovative drugs, accelerating the customer linesinto key clinical phases and achieving successful launch of products, so as tobenefit the public with high-quality medicines earlier.
Mr. Meijie Le, CEO ofEvopoint, said that: “The professionalism and engagement of Porton's team havebeen proven through the past 5 years of cooperation. Cooperation with Portonhas accelerated the development and commercialization of important innovativedrug lines in Evopoint, and our team is confident in the broad prospects of ourown product lines. We are very pleased to sign this strategic cooperationagreement with Porton, which points out that Porton will provide Evopoint withcomprehensive CDMO services and support Evopoint in developing andcommercializing differentiated innovative drug products worldwide. The signingof this agreement is an important milestone, marking that many products in Evopointare about to be involved into late-stage clinical trials andcommercialization.”
Mr. Nianfeng Ju, one of theco-founders, chairman and general manager of Porton, said that: “The strategicpartnership with Evopoint marks a new stage of cooperation in the past 5 yearsbetween the two parties, suggesting mutual trust and recognition between Portonand Evopoint. Evopoint is committed to providing solutions to unmet clinicalneeds worldwide, and several product lines in Evopoint are undergoing clinicaltrials. We are looking forward to providing Evopoint with professional,efficient and reliable CDMO services, accelerating the development andmarketing of their products in both China and the United States, and benefitingpatients as soon as possible.”
About Porton
